Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accumulated Expenses (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Accumulated Expenses for 7 consecutive years, with $28.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 6.26% to $28.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.2 million through Dec 2025, down 6.26% year-over-year, with the annual reading at $28.2 million for FY2025, 6.26% down from the prior year.
  • Accumulated Expenses hit $28.2 million in Q4 2025 for Allogene Therapeutics, roughly flat from $28.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $44.6 million in Q1 2023 to a low of $24.4 million in Q2 2024.
  • Historically, Accumulated Expenses has averaged $32.9 million across 5 years, with a median of $31.2 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 102.53% in 2021 and later crashed 44.94% in 2024.
  • Year by year, Accumulated Expenses stood at $37.5 million in 2021, then grew by 5.99% to $39.7 million in 2022, then dropped by 21.54% to $31.2 million in 2023, then dropped by 3.38% to $30.1 million in 2024, then dropped by 6.26% to $28.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for ALLO at $28.2 million in Q4 2025, $28.1 million in Q3 2025, and $26.8 million in Q2 2025.